Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis

Circulation

Volumn 127, Issue 4, 2013, Pages 424-434

  Anisimov, Andrey ^a,b   Tvorogov, Denis ^b   Alitalo, Annamari ^a   Leppänen, Veli Matti ^a,b   An, Yuri ^d   Han, Eun Chun ^d   Orsenigo, Fabrizio ^e   Gaál, Emília Ilona ^a,b   Holopainen, Tanja ^b   Koh, Young Jun ^d   Tammela, Tuomas ^b   Korpisalo, Petra ^c   Keskitalo, Salla ^b   Jeltsch, Michael ^b   Ylä Herttuala, Seppo ^c   Dejana, Elisabetta ^e,f   Koh, Gou Young ^d   Choi, Chulhee ^d   Saharinen, Pipsa ^a,b   Alitalo, Kari ^a,b,c,g  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^e FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g SWISS FEDERAL INSTITUTE OF TECHNOLOGY   (Switzerland)

Author keywords

Angiogenesis inducers; Capillary permeability; Gene therapy; Ischemia; Vascular endothelium

Indexed keywords

ANGIOPOIETIN 1; CADHERIN; CHIMERIC PROTEIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; ENDOCYTOSIS; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; INFLAMMATORY CELL; LIMB ISCHEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; RECEPTOR BINDING; SKELETAL MUSCLE; TRANSGENE;

ADENOVIRIDAE; ANGIOPOIETIN-1; ANIMALS; CAPILLARY PERMEABILITY; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GENETIC THERAPY; HEK293 CELLS; HINDLIMB; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; ISCHEMIA; LEUKEMIA, MYELOID; MICE; MICE, INBRED STRAINS; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTOR PROTEIN-TYROSINE KINASES; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84873104951     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.127472     Document Type: Article

References (50)

1. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2009;29:789-791.
2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438:932-936. (Pubitemid 43093958)
3. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8:464-478. (Pubitemid 46823443)
4. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res. 2009;105:724-736.
5. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis. 2008;11:109-119.
6. Shibuya M, Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res. 2006;312:549-560. (Pubitemid 43290332)
7. Inoue N, Kondo T, Kobayashi K, Aoki M, Numaguchi Y, Shibuya M, Murohara T. Therapeutic angiogenesis using novel vascular endothelial growth factor-E/human placental growth factor chimera genes. Arterioscler Thromb Vasc Biol. 2007;27:99-105. (Pubitemid 46360385)
8. Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, Silvola J, Saraste A, Jeltsch M, Korpisalo P, Carmeliet P, Lemström KB, Shibuya M, Ylä-Herttuala S, Alhonen L, Mervaala E, Andersson LC, Knuuti J, Alitalo K. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation. 2010;122:1725-1733.
9. Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, Kholová I, Kauppinen RA, Achen MG, Stacker SA, Alitalo K, Ylä-Herttuala S. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res. 2003;92:1098-1106. (Pubitemid 36665855)
10. Anisimov A, Alitalo A, Korpisalo P, Soronen J, Kaijalainen S, Leppänen VM, Jeltsch M, Ylä-Herttuala S, Alitalo K. Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ Res. 2009;104:1302-1312.
11. Keskitalo S, Tammela T, Lyytikka J, Karpanen T, Jeltsch M, Markkanen J, Yla-Herttuala S, Alitalo K. Enhanced capillary formation stimulated by a chimeric vascular endothelial growth factor/vascular endothelial growth factor-C silk domain fusion protein. Circ Res. 2007;100:1460-1467. (Pubitemid 46834758)
12. Leppänen VM, Jeltsch M, Anisimov A, Tvorogov D, Aho K, Kalkkinen N, Toivanen P, Ylä-Herttuala S, Ballmer-Hofer K, Alitalo K. Structural determinants of vascular endothelial growth factor-D receptor binding and specificity. Blood. 2011;117:1507-1515.
13. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 2009;10:165-177.
14. Kim I, Moon SO, Park SK, Chae SW, Koh GY. Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res. 2001;89:477-479. (Pubitemid 34132640)
15. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, Mc-Donald DM. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science. 1999;286:2511-2514.
16. Su H, Takagawa J, Huang Y, Arakawa-Hoyt J, Pons J, Grossman W, Kan YW. Additive effect of AAV-mediated angiopoietin-1 and VEGF expression on the therapy of infarcted heart. Int J Cardiol. 2009;133:191-197.
17. Chen F, Tan Z, Dong C Y, Chen X, Guo SF. Adeno-associated virus vectors simultaneously encoding VEGF and angiopoietin-1 enhances neovascularization in ischemic rabbit hind-limbs. Acta Pharmacol Sin. 2007;28:493-502. (Pubitemid 46496081)
18. Kim KT, Choi HH, Steinmetz MO, Maco B, Kammerer RA, Ahn SY, Kim HZ, Lee GM, Koh GY. Oligomerization and multimerization are critical for angiopoietin-1 to bind and phosphorylate Tie2. J Biol Chem. 2005;280:20126-20131. (Pubitemid 41379543)
19. Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC, De Vos AM. Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site. Proc Natl Acad Sci USA. 1997;94:7192-7197. (Pubitemid 27345291)
20. Cho CH, Kammerer RA, Lee HJ, Steinmetz MO, Ryu YS, Lee SH, Yasunaga K, Kim KT, Kim I, Choi HH, Kim W, Kim SH, Park SK, Lee GM, Koh G Y. COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity. Proc Natl Acad Sci USA. 2004;101:5547-5552. (Pubitemid 38481194)
21. Xu Y, Yu Q. Angiopoietin-1, unlike angiopoietin-2, is incorporated into the extracellular matrix via its linker peptide region. J Biol Chem. 2001;276:34990-34998.
22. Leppänen VM, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, Lankinen H, Goldman A, Ballmer-Hofer K, Alitalo K. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proc Natl Acad Sci USA. 2010;107:2425-2430.
23. Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A, Winderlich M, Nottebaum A, Vestweber D, Deutsch U, Koh GY, Olsen BR, Alitalo K. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat Cell Biol. 2008;10:527-537. (Pubitemid 351627372)
24. Fukuhara S, Sako K, Minami T, Noda K, Kim HZ, Kodama T, Shibuya M, Takakura N, Koh GY, Mochizuki N. Differential function of Tie2 at cellcell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat Cell Biol. 2008;10:513-526. (Pubitemid 351627371)
25. Yuan HT, Khankin EV, Karumanchi SA, Parikh SM. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol. 2009;29:2011-2022.
26. Findley CM, Cudmore MJ, Ahmed A, Kontos CD. VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vasc Biol. 2007;27:2619-2626. (Pubitemid 350158914)
27. Yabkowitz R, Meyer S, Black T, Elliott G, Merewether LA, Yamane HK. Inflammatory cytokines and vascular endothelial growth factor stimulate the release of soluble tie receptor from human endothelial cells via metalloprotease activation. Blood. 1999;93:1969-1979. (Pubitemid 29128499)
28. Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol. 2006;8:1223-1234. (Pubitemid 44660587)
29. Gavard J, Patel V, Gutkind JS. Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev Cell. 2008;14:25-36.
30. Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angiomagenesis? Nat Med. 2000;6:1102-1103.
31. Kang Y, Choi M, Lee J, Koh GY, Kwon K, Choi C. Quantitative analysis of peripheral tissue perfusion using spatiotemporal molecular dynamics. PLoS One. 2009;4:e4275.
32. Davis S, Papadopoulos N, Aldrich TH, Maisonpierre PC, Huang T, Kovac L, Xu A, Leidich R, Radziejewska E, Rafique A, Goldberg J, Jain V, Bailey K, Karow M, Fandl J, Samuelsson SJ, Ioffe E, Rudge JS, Daly TJ, Radziejewski C, Yancopoulos GD. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol. 2003;10:38-44. (Pubitemid 36034175)
33. Lampugnani MG, Zanetti A, Corada M, Takahashi T, Balconi G, Breviario F, Orsenigo F, Cattelino A, Kemler R, Daniel TO, Dejana E. Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148. J Cell Biol. 2003;161:793-804. (Pubitemid 36648762)
34. Winderlich M, Keller L, Cagna G, Broermann A, Kamenyeva O, Kiefer F, Deutsch U, Nottebaum AF, Vestweber D. VE-PTP controls blood vessel development by balancing Tie-2 activity. J Cell Biol. 2009;185:657-671.
35. Gampel A, Moss L, Jones MC, Brunton V, Norman JC, Mellor H. VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment. Blood. 2006;108:2624-2631.
36. Lampugnani MG, Orsenigo F, Gagliani MC, Tacchetti C, Dejana E. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J Cell Biol. 2006;174:593-604. (Pubitemid 44231870)
37. Lanahan AA, Hermans K, Claes F, Kerley-Hamilton JS, Zhuang ZW, Giordano FJ, Carmeliet P, Simons M. VEGF receptor 2 endocytic trafficking regulates arterial morphogenesis. Dev Cell. 2010;18:713-724.
38. Dejana E, Orsenigo F, Molendini C, Baluk P, McDonald DM. Organization and signaling of endothelial cell-to-cell junctions in various regions of the blood and lymphatic vascular trees. Cell Tissue Res. 2009;335:17-25.
39. Zanetti A, Lampugnani MG, Balconi G, Breviario F, Corada M, Lanfrancone L, Dejana E. Vascular endothelial growth factor induces SHC association with vascular endothelial cadherin: a potential feedback mechanism to control vascular endothelial growth factor receptor-2 signaling. Arterioscler Thromb Vasc Biol. 2002;22:617-622. (Pubitemid 34408743)
40. Nambu H, Nambu R, Oshima Y, Hackett SF, Okoye G, Wiegand S, Yancopoulos G, Zack DJ, Campochiaro PA. Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier. Gene Ther. 2004;11:865-873. (Pubitemid 38714590)
41. Uemura A, Ogawa M, Hirashima M, Fujiwara T, Koyama S, Takagi H, Honda Y, Wiegand SJ, Yancopoulos GD, Nishikawa S. Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J Clin Invest. 2002;110:1619-1628. (Pubitemid 35424240)
42. Devi TS, Singh LP, Hosoya K, Terasaki T. GSK-3β/CREB axis mediates IGF-1-induced ECM/adhesion molecule expression, cell cycle progression and monolayer permeability in retinal capillary endothelial cells: implications for diabetic retinopathy. Biochim Biophys Acta. 2011;1812:1080-1088.
43. Van Wetering S, Van Den Berk N, Van Buul JD, Mul FP, Lommerse I, Mous R, Ten Klooster JP, Zwaginga JJ, Hordijk PL. VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration. Am J Physiol Cell Physiol. 2003;285:C343-C352. (Pubitemid 36917849)
44. Baffert F, Le T, Thurston G, McDonald DM. Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules. Am J Physiol Heart Circ Physiol. 2006;290:H107-H118.
45. Fukino K, Sata M, Seko Y, Hirata Y, Nagai R. Genetic background influences therapeutic effectiveness of VEGF. Biochem Biophys Res Commun. 2003;310:143-147. (Pubitemid 37162774)
46. Urano T, Ito Y, Akao M, Sawa T, Miyata K, Tabata M, Morisada T, Hato T, Yano M, Kadomatsu T, Yasunaga K, Shibata R, Murohara T, Akaike T, Tanihara H, Suda T, Oike Y. Angiopoietin-related growth factor enhances blood flow via activation of the ERK1/2-eNOS-NO pathway in a mouse hindlimb ischemia model. Arterioscler Thromb Vasc Biol. 2008;28:827-834. (Pubitemid 351544095)
47. Von Degenfeld G, Banfi A, Springer ML, Wagner RA, Jacobi J, Ozawa CR, Merchant MJ, Cooke JP, Blau HM. Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia. FASEB J. 2006;20:2657-2659.
48. Shimpo M, Ikeda U, Maeda Y, Takahashi M, Miyashita H, Mizukami H, Urabe M, Kume A, Takizawa T, Shibuya M, Ozawa K, Shimada K. AAV-mediated VEGF gene transfer into skeletal muscle stimulates angiogenesis and improves blood flow in a rat hindlimb ischemia model. Cardiovasc Res. 2002;53:993-1001. (Pubitemid 34261037)
49. Dor Y, Djonov V, Abramovitch R, Itin A, Fishman GI, Carmeliet P, Goelman G, Keshet E. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 2002;21:1939-1947. (Pubitemid 34437191)
50. Reginato S, Gianni-Barrera R, Banfi A. Taming of the wild vessel: promoting vessel stabilization for safe therapeutic angiogenesis. Biochem Soc Trans. 2011;39:1654-1658.